CTLA4 and pneumonitis: This meta-analysis, which included 4,164 patients treated with CTLA-4 inhibitors (either as monotherapy or in combination therapy), found an overall incidence of any-grade pneumonitis of 4.0% [95% CI (2.2%, 5.8%)].